Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nurix Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NRIX
Nasdaq
8731
https://www.nurixtx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nurix Therapeutics Inc
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
- May 7th, 2024 11:00 am
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Apr 16th, 2024 10:21 pm
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
- Apr 15th, 2024 11:31 am
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
- Apr 12th, 2024 3:38 am
Nurix Therapeutics Announces Proposed Public Offering
- Apr 11th, 2024 8:00 pm
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
- Apr 11th, 2024 1:30 pm
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
- Apr 10th, 2024 1:29 pm
Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
- Apr 10th, 2024 12:31 pm
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
- Apr 10th, 2024 12:10 pm
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
- Apr 10th, 2024 11:00 am
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
- Apr 9th, 2024 5:15 pm
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
- Apr 9th, 2024 11:00 am
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
- Apr 4th, 2024 11:52 am
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Apr 3rd, 2024 11:00 am
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
- Apr 2nd, 2024 11:00 am
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
- Mar 25th, 2024 11:00 am
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
- Mar 20th, 2024 1:40 pm
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
- Mar 11th, 2024 11:00 am
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
- Mar 5th, 2024 9:30 pm
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
- Feb 23rd, 2024 11:20 am
Scroll